Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Evanthia Galanis(Mayo Clinic in Arizona), Daniel J. Walsh(University College Cork)
Journal of Clinical Oncology
July 6, 2005
Cited by 695


Related Papers